InterVenn Presents Results at American Society for Mass Spectrometry Conference Demonstrating that Differential Peripheral Blood Glycoproteomic Signatures are Associated with Symptomatic vs. Asymptomatic Course of COVID-19 Infection
PHILADELPHIA–(BUSINESS WIRE)–#AI—InterVenn Biosciences, the leader in glycoproteomics, presented results today on the application of its perspectIV™ platform in COVID-19 patients, demonstrating that glycoproteomic profiles in patients with a severe course of the infection are significantly different from those who experienced an asymptomatic course of the infection. InterVenn’s proprietary perspectIV™ platform is capable of interrogating the blood glycoproteome at a depth and scale heretofore never possible, using a unique combination of mass-spectrometry and proprietary AI-powered software, opening up a whole new domain of biology to the identification of novel biomarkers and diagnostic tools for a broad range of applications.
Results were presented today at the American Society for Mass Spectrometry Conference from a study conducted including samples of patients who had been seriously ill with COVID-19, of individuals who had an asymptomatic course of COVID-19, and of other patients, as additional references, who had been diagnosed with either bacterial sepsis, common-cold coronavirus, or who were healthy controls. The study results show that there are statistically highly significant glycoproteomic profiles differentiating severe from asymptomatic COVID-19. Of interest, while a number of glycoproteomic attributes were shared between patients suffering from symptomatic COVID-19 and bacterial sepsis, likely representative of a systemic inflammatory response, a subset of glycoproteomic biomarkers were specific to severe COVID-19, potentially providing insights into specific pathological consequences of, or a particular predisposition for, a severe course of the infection.
“These results highlight yet another clinically important use application of perspectIV™ and the potential of glycoproteomics to discover new biomarkers and novel insights into pathobiology,” said Aldo Carrascoso, CEO and co-founder of InterVenn.
To find out more about InterVenn Biosciences or partnership opportunities, visit https://intervenn.com. For all media inquiries about InterVenn Biosciences, please contact Andrea Vuturo at email@example.com
About InterVenn Biosciences
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression.
Tel: (888) 706-1670